Bristol-Myers Squibb Company (NYSE: BMY)
Health Care · Pharmaceuticals · US
$67.16
-0.18% today · +42.7% 1Y
Bristol-Myers Squibb Company (NYSE: BMY) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $137.43B and employs 32,500 people.
Over the last twelve months the share price has gained 42.7%, trading between 42.52 and 68.64.
Tweenvest scores Bristol-Myers Squibb Company across four factors: quality 76/100, value 39/100, growth 23/100, dividend 80/100. Its strongest factor is dividend.
BMY price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $137.43B
- Revenue (TTM)
- $49.19B
- P/E
- 14.81
- EPS
- 4.54
- Dividend yield
- 3.76%
- Beta (5Y)
- 0.22
- 52-week high
- $68.64
- 52-week low
- $42.52
- Avg volume (3M)
- —
- Shares outstanding
- 2.04B
- Employees
- 32,500
- Next earnings
- —
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- ISIN
- US1101221083
- Founded
- 1887
- Listed since
- Jun 1, 1972
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,243.44 | -0.28% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $270.51 | -0.93% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.36 | -0.20% |
| Roche Holding AGSWX: ROP | $368.80B | CHF371.30 | +0.24% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £122.24 | +0.94% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.92 | -0.18% |
Figures last refreshed Aug 18, 2026.